Each week we highlight five things affecting the life sciences industry. Here's the latest. Global health care’s push for climate resilience Following NHS England's 2020 commitment to net zero emissions by 2045, over 20 countries are adopting similar goals, aiming to create climate-resilient health ... READ MORE >
pharmaceuticals
5 things to know in life sciences: Week of Oct. 16, 2023
This week we delve into the pharmaceutical industry’s reputation among neurology patient groups. Also, the biopharma industry continues to make substantial investments in mergers and acquisitions, and Korean contract development and manufacturing organizations struggle to meet the needs of the cell and ... READ MORE >
5 things to know in life sciences: Week of November 15
This week we look at the Food and Drug Administration’s approval of a virtual reality system to treat chronic lower back pain. We also explore a new round of anti-amyloid drugs seeking FDA approval to treat Alzheimer’s disease, a sustainable method to manufacture pharmaceuticals, another deal to license ... READ MORE >
CHART OF THE DAY: FTC challenges biopharma merger as antitrust scrutiny grows
Less than two weeks after the Federal Trade Commission announced it would be taking a more stringent look at mergers in the biopharmaceutical industry, the proposed Illumina and Grail merger became only the second vertical merger in 40 years (2017’s proposed merger between AT&T and Time Warner) to be ... READ MORE >
5 things to know in life sciences: Week of March 15
The Federal Trade Commission’s new acting chair, Rebecca Kelly Slaughter, has initiated a review of the agency's processes for approving pharma mergers. This is expected to result in a tougher road for these mergers, as we explain below. We also look at the top drugs losing their exclusivity this year, ... READ MORE >
5 things to know in life sciences: Week of March 1
In this week’s roundup we look at new data coming out of the United Kingdom and Israel on their COVID-19 vaccination programs’ results. The U.K. reported last week promising data on the efficacy of the Pfizer-BioNTech vaccine after just one dose. We also highlight improvements in public perception of the ... READ MORE >
5 things to know in life sciences: Week of Jan. 25
This week’s roundup includes several reads about a crucial but often unnoticed shift in the life sciences ecosystem—the interplay between the digital future of life science, the development of next generation therapeutics, and the promise of personalized medicine. The drop in cost and increase in ... READ MORE >
5 things to know this week in life sciences: Week of Jan. 11
In this week’s roundup, we take a look at life sciences fundraising totals from 2020, which was a record year for the industry in the capital markets. Silicon Valley Bank provides a detailed look at the numbers and provides insights into what to expect this year. Other news this week included Bluebird ... READ MORE >
5 things to know this week in life sciences: Week of Jan. 4
Each year, pharma companies make updates to their price lists in January. This reliably generates headlines and, occasionally, congressional hearings. In this week’s industry roundup, we take a look at the recent price increases and how they compare to last year’s. We also look at the ongoing battle over ... READ MORE >
5 things to know this week in life sciences: Week of Dec. 21
With approval of Moderna’s COVID-19 vaccine last week for emergency use, many of us are looking forward to getting vaccinated with the hope that it will help us return to a more normal life. While looking forward, this is also a good time to reflect on the decades of work that laid the groundwork for this ... READ MORE >